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Objective
An important asthma therapy goal is to limit short-acting
b2-agonist (SABA) rescue medication use. We evaluated
the effect of mometasone furoate/formoterol (MF/F)
combination therapy on SABA use with data from 3
phase III studies.
Methods
All studies enrolled subjects (≥12y) with persistent
asthma not well controlled on inhaled corticosteroids
(ICS): study 1 (n=746 subjects with moderate persistent
asthma randomized to 26wk MF/F-100/10µg, MF-100µg,
F-10µg, or placebo twice daily [BID]); study 2 (n=781
subjects with moderate persistent asthma randomized to
26wk MF/F-200/10µg, MF-200µg, F-10µg, or placebo
BID); study 3 (n=728 subjects with severe persistent
asthma randomized to 12wk MF/F-400/10µg, MF/F-200/
10µg, or MF-400µg BID). All studies included a 2-3wk
MF BID run-in: P04073 (100µg), P04334(200µg), P04431
(400µg). Percentage of SABA-free days/nights was a pre-
defined secondary endpoint in all studies.
Results
In study 1, mean change in the percentage of SABA-free
days/ nights from baseline period (day -7 to 1) to overall
treatment period was significantly increased for MF/F-
100/10µg (18%) vs F-10µg (10%) and placebo (0% P≤.003),
and numerically increased for MF/F-100/10µg vs MF-
100µg (14%). In study 2, change in SABA-free days/nights
was significantly increased for MF/F-200/10µg (21%) vs
MF-200µg (15%), F-10µg (11%), and placebo (5%; P≤.033).
In study 3, change in SABA-free days/nights was
significantly increased for MF/F-400/10µg and MF/F-200/
10µg groups (25% increase for each) vs the MF-400µg
group (13%; P<.001).
Conclusion
MF/F treatment resulted in significant improvement in
the frequency of SABA-free days/nights vs individual
MF and/or F monotherapies in subjects with persistent
asthma not well controlled on ICS therapy.
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